Study: Selumetinib promotes radioiodine absorption in thyroid cancer

02/13/2013 | MedPage Today (free registration)

A new kinase inhibitor called selumetinib made advanced thyroid cancer more susceptible to radioiodine, especially in patients with RAS mutations in their disease, according to a study published in the New England Journal of Medicine. The drug restored or increased the absorption of iodine in 12 of 20 patients who were previously resistant to radioiodine, according to findings on PET images. "These results provide a proof of principle that MEK inhibitors can induce iodine uptake and retention in thyroid tumors," researchers said.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC